NASDAQ: AFIBAcutus Medical Inc Stock
$0.17+0.00 (+0%)
Updated Apr 19, 2024
AFIB Price
$0.17
Fair Value Price
$0.97
Market Cap
$5.05M
52 Week Low
$0.16
52 Week High
$1.09
P/E
-0.06x
P/B
-5.75x
P/S
0.83x
PEG
N/A
Dividend Yield
N/A
Revenue
$7.16M
Earnings
-$81.66M
Gross Margin
-43.8%
Operating Margin
-1,060.09%
Profit Margin
-1,139.9%
Debt to Equity
-62.39
Operating Cash Flow
-$63M
Beta
1.18
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A
AFIB Overview
Acutus Medical, Inc., an arrhythmia management company, designs, manufactures, and markets a range of tools for catheter-based ablation procedures to treat various arrhythmias in the United States and internationally. The company's product portfolio includes novel access sheaths, transseptal crossing tools, diagnostic and mapping catheters, conventional and contact force ablation catheters, and mapping and imaging consoles and accessories, as well as supporting algorithms and software programs. Acutus Medical, Inc. was incorporated in 2011 and is headquartered in Carlsbad, California.
Zen Score
–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how AFIB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AFIB ($0.17) is undervalued by 82.45% relative to our estimate of its Fair Value price of $0.97 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
AFIB ($0.17) is significantly undervalued by 82.45% relative to our estimate of its Fair Value price of $0.97 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
AFIB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more AFIB due diligence checks available for Premium users.
Be the first to know about important AFIB news, forecast changes, insider trades & much more!
AFIB News
Valuation
AFIB fair value
Fair Value of AFIB stock based on Discounted Cash Flow (DCF)
Price
$0.17
Fair Value
$0.97
Undervalued by
82.45%
AFIB ($0.17) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
AFIB ($0.17) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
AFIB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
AFIB price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.06x
Industry
28.69x
Market
40.51x
AFIB price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-5.75x
Industry
3.63x
AFIB's financial health
Profit margin
Revenue
-$7.5M
Net Income
-$33.8M
Profit Margin
448.3%
AFIB's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
AFIB's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$54.0M
Liabilities
$54.8M
Debt to equity
-62.39
AFIB's short-term assets ($46.25M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AFIB's short-term assets ($46.25M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AFIB's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
AFIB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$18.0M
Investing
$11.2M
Financing
-$495.0k
AFIB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
AFIB vs Medical Device Stocks
Acutus Medical Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.